Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;29(10):6350-6358.
doi: 10.1245/s10434-022-12129-4. Epub 2022 Jul 8.

Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma

Isabelle L Crary  1 , Elizabeth U Parker  2 , Kathryn P Lowry  3 , Pranav P Patwardhan  4 , Thing Rinda Soong  4 , Sara H Javid  5 , Kristine E Calhoun  5 , Meghan R Flanagan  6   7
Affiliations

Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma

Isabelle L Crary et al. Ann Surg Oncol. 2022 Oct.

Abstract

Background: Atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ encompass a spectrum of proliferative lesions known as lobular neoplasia (LN). When imaging-concordant and found in isolation on core needle biopsy (CNB), LN infrequently upgrades to carcinoma on surgical excision, and routine excision is not indicated. Upgrade rates in the setting of synchronous carcinoma are not well studied.

Patients and methods: Patients with radiology-pathology concordant synchronous LN and separately biopsied ipsilateral (n = 35) or contralateral (n = 15) carcinoma who underwent excision between 2010 and 2021 were retrospectively identified. Frequency of upgrade, to either invasive or in situ carcinoma, was quantified, and factors associated with upgrade were assessed using Fisher's exact test.

Results: The median age was 55 (range 33-74) years. The upgrade rate of LN was 6% and not significantly different between ipsilateral (2.9%) and contralateral (13.3%) carcinoma (p = 0.15). All upgraded LN lesions were ALH on CNB and detected as non-mass enhancement on magnetic resonance imaging (MRI). No additional disease was demonstrated after excision at the site of the original LN CNB in 22.9% (8 out of 35) of ipsilateral and 13.3% (2 out of 15) of contralateral patients. Upgrade was not associated with family history, menopausal status, imaging modality used to detect LN, or extent of LN on CNB (p > 0.05).

Conclusions: Our results demonstrate a low upgrade rate (6%) in our study cohort of LN with synchronous ipsilateral or contralateral carcinoma, which suggests that not all LN mandates excision with synchronous carcinoma. Larger, multi-institution studies are needed to validate these findings.

PubMed Disclaimer

Comment in

References

    1. Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2002;75:259–68. https://doi.org/10.1023/a:1019950918046 . - DOI
    1. Oppong BA, King TA. Recommendations for women with lobular carcinoma in situ (LCIS). J Oncol. 2011;25(11):1051–6.
    1. Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, DePeri ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19(10):3131–8. https://doi.org/10.1245/s10434-012-2534-9 . - DOI - PubMed
    1. Sen LQC, Berg WA, Hooley RJ, Carter GJ, Desouki MM, Sumkin JH. Core breast biopsies showing lobular carcinoma in situ should be excised and surveillance is reasonable for atypical lobular hyperplasia. Am J Roentgenol. 2016;207(5):1132–45. https://doi.org/10.2214/AJR.15.15425 . - DOI
    1. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–496.3. https://doi.org/10.3322/canjclin.32.4.234 . - DOI - PubMed - PMC